| HOME >> BIOLOGY >> TECHNOLOGY |
Operating income 11,662 5,844
Other income (expenses), net:
Other income (expenses), net 2,807 840
Interest income (expenses), net 516 (629)
Total other income (expenses), net 3,323 211
Income before income taxes 14,985 6,055
Income taxes (1,124) (78)
Net income 13,861 5,977
Income (loss) attributable to
holders of ADS:
Basic 13,861 (1,635)
Diluted 13,861 (1,635)
Basic earnings (loss) per ADS 0.22 (0.06)
Diluted earnings (loss) per ADS 0.19 (0.06)
Number of shares used in
calculation (Note 3):
Weighted average ADS outstanding
- basic 61,895,469 25,329,825
Weighted average ADS outstanding
- diluted 72,416,243 25,329,825
Note 3: One (1) ADS equals eight (8) ordinary shares
WUXI PHARMATECH (CAYMAN) INC.
RECONCILIATION OF NON-GAAP TO GAAP
(in thousands of US Dollars, except per ADS data)
Three Months Ended March 31,
2008 2007
GAAP net income 13,861 5,977
Add: Share-based compensation expenses 2,978 3,352
Amortization of acquired intangible assets 446 --
Non-GAAP net income
'/>"/>
| SOURCE WuXi PharmaTech Copyright©2008 PR Newswire. All rights reserved |